JPRN-UMIN000026093已完成1 期
Phase I study of Vinorelbine(VNR) and S-1 combination therapy for the elderly patients with advanced non-small-cell lung cancer. - Phase I study of VNR and S-1 combination therapy.
Tokyo Metropolitan Tama Medical Center Department of respiratory medicine and clinical oncology0 个研究点目标入组 9 人开始时间: 2017年2月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Symptomatic brain metastasis 2) Severe infection 3) Severe comorbidity (heart failure Tendency to hemorrhages uncontrollable hypertension, uncontrollable diabetes, etc) 4)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 5) Planning of surgery or thoracic radiotherapy during the trial. 6) With a history of drug sensitivity for S-1 or Vinorelbine. 7) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
研究者
相似试验
已完成
1 期
Phase I and II study of S-1+vinorelbine in patients with advanced non-small cell cancerunresectable non-small cell lung cancerJPRN-UMIN000030999Tottori University35
已完成
1 期
A phase I study of vinorelbine concurrent with thoracic radiotherapy in elderly patients with l locally advanced non-small cell lung cancer(WJTOG 3005).on-small cell lung cancerJPRN-UMIN000001392West Japan Oncology Group20
招募中
2 期
Phase II Study of Vinorelbine + TS-1 in Patients with EGFR-mutated Advanced Non-small Cell Lung CancerJPRN-UMIN000016765Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University37
进行中（未招募）
1 期
Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes)EUCTR2004-000665-35-ESPierre Fabre Medicament
已完成
2 期
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast CancerHer2-negative Metastatic Breast CancerHer2-negative Locally Advanced Breast CancerNCT01520103AIO-Studien-gGmbH139